If you deal with recurrent UTIs, a new FDA-approved antibiotic called Blujepa could offer another treatment option—especially ...

Pharma is missing opportunities to maximise the benefits of applying a digital approach on a global scale, says Gregg Fisher. Managing for global impact continues to be a challenge for many ...

European regulators have refused to back GlaxoSmithKline’s daily triple therapy Trelegy Ellipta for asthma, denying a label extension because there was no evidence to show a reduction of flare-ups.